Skip to main content
Clinical Trials/NCT03725917
NCT03725917
Unknown
Not Applicable

Efficacy of a Protocol of Intervention in Physiotherapy in the Prevention of Diabetic Foot Ulcers in Patients With Diabetic Neuropathy

Universidad Complutense de Madrid1 site in 1 country143 target enrollmentMarch 25, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetic Foot Ulcer
Sponsor
Universidad Complutense de Madrid
Enrollment
143
Locations
1
Primary Endpoint
Change in the integrity of the skin (Ulceration)
Last Updated
7 years ago

Overview

Brief Summary

This study evaluates the effects of a physiotherapy protocol (manual therapy and exercise) in the prevention of diabetic foot ulcers in patients with diabetic neuropathy. A group of participants will receive a physiotherapy protocol added to their usual medical treatment and the other group will not receive physiotherapy treatment.

Detailed Description

Neuropathic diabetic patients present alterations in joint mobility, plantar pressures and ankle and foot function, characteristics related to the development of ulcers. In previous studies, it has been observed that physiotherapy protocols have produced improvements in joint mobility, magnitude of plantar pressures, distribution of plantar pressures, and improved function in the ankle and foot. A 12-week progressive physiotherapy protocol composed of manual therapy and exercise could produce changes in foot and ankle characteristics in diabetic neuropathic patients related to tissue damage, resulting in a reduction in ulcerations.

Registry
clinicaltrials.gov
Start Date
March 25, 2019
End Date
December 1, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Guido Gomez Chiguano

Clinical Research

Universidad Complutense de Madrid

Eligibility Criteria

Inclusion Criteria

  • Participants with diabetes mellitus type 1 or type 2
  • Patients with diabetic neuropathy
  • Patients with no previous history of ulcers
  • Patients with no previous history of lower limb amputations

Exclusion Criteria

  • Patients with neurological or orthopedic problems that make walking difficult (spasticity, cerebral palsy, poliomyelitis, rheumatoid arthritis)
  • Severe vascular complications (arterial or venous ulcers)
  • Patients with critical ischemia
  • Patient who need walking aids (canes, crutches, splints etc.)
  • Patients with a history of neuropathy with different etiology from diabetes mellitus.
  • Patients with peripheral nervous lesions (traumatic origin, associated with surgical procedures, compression of spinal roots, plexus palsy, herpes zoster, polyradiculopathy, etc.)

Outcomes

Primary Outcomes

Change in the integrity of the skin (Ulceration)

Time Frame: Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks

An ulcer is considered a full thickness wound below the ankle in a diabetic patient, regardless of duration, including gangrene and necrosis. The evaluator will review the patient's medical records on the day of the evaluations, in order to assess if there has been an ulceration in the periods between evaluations and also perform a foot exploration to assess if the ulcer is present on the day of measurement. The Wagner system assesses ulcer depth and the presence of osteomyelitis or gangrene using the following grades: grade 0 (pre- or post-ulcerative lesion), grade 1 (partial/full-thickness ulcer), grade 2 (probing to tendon or capsule), grade 3 (deep with osteitis), grade 4 (partial foot gangrene) and grade 5 (whole foot gangrene).

Secondary Outcomes

  • Change in foot function index(Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks)
  • Changes in the integral pressure-time(Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks)
  • Change in confidence in the balance for specific activities(Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks)
  • Change in joint mobility(Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks)
  • Change in neurological function of the foot(Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks)
  • Change in maximum plantar pressure(Clinical evaluation will be conducted at pre-treatment, post- treatment 12 weeks, post- treatment 24 weeks, post- treatment 36 weeks, post- treatment 48 weeks and post- treatment 60 weeks)

Study Sites (1)

Loading locations...

Similar Trials